Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart.

The researchers used a continuous glucose monitoring system (CGMS) and self-reported episodes to investigate differences in the frequency of low glucose values in patients with type 2 diabetes, using either biphasic insulin aspart 30 (BIAsp 30) or biphasic human insulin 30 (BHI 30).

Who Took Part

The study group was 160 subjects.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

This was a double-blind, two-period, crossover trial involving 160 subjects.

After 8 weeks' run-in, subjects were randomized to the first of two 16-week treatment periods.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The subjects were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Blinding on both sides kept the subjects and researchers unaware of who received Insulin Aspart.

In the crossover set-up each of the subjects took both Insulin Aspart and the comparison in turn, acting as their own control.

A time span of 8 weeks appears in the methods.

What Was Measured

Topics PubMed links to this paper include Biphasic Insulins, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 160 subjects over 8 weeks.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (Diabetes care), a journal based in United States.

More context: the Insulin Aspart compound page.